Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Siemens, Other Top Dx Firms Wax Molecular At AACC Lab Conference

This article was originally published in The Gray Sheet

Executive Summary

Siemens bought its way to the top of the in vitro diagnostics market during the past two years and is now aiming to make gains in one of the fastest growing segments of that sector - molecular diagnostics

You may also be interested in...



Abbott Diagnostics Unit Teams Up With Big Pharma On Companion Test

Abbott's molecular diagnostics business announced March 7 a collaboration with Genentech, Roche and OSI Pharmaceuticals to develop a gene test that helps select patients more likely to respond to the lung cancer drug Tarceva

Ibis Prepares Next-Gen Microorganism Detector For Diagnostic Space

Five years ago the U.S. Department of Defense commissioned California-based Isis Pharmaceuticals to develop a new technology to more easily detect bioterrorism agents. Now, $55.6 million in government grants later, the company is readying the Ibis T5000 Biosensor System to make its way into the in vitro diagnostics space

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT026418

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel